Updated results from clinical trial with Diamyd® presented today at diabetes conference

Updated 12-month results from the open-label investigator-initated Phase II clinical trial GADinLADA that assessed three intralymphatic injections of the therapeutic diabetes vaccine Diamyd[®] in individuals diagnosed with Latent Autoimmune Diabetes in Adults (LADA) were presented today at the European Association for the Study of Diabetes (EASD) conference in Stockholm, Sweden. The updated results provide further support to the previously reported topline results that showed a positive immunological and metabolic response to Diamyd[®] treatment in individuals diagnosed LADA who carries the